IMPACT OF WBC COUNT ON ADMISSION ON EARLY AND LONG-TERM MORTALITY IN PATINETS TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Abstract
ABSTRACT
Introduction: Inflammation plays a key role in the process of atherosclerosis, its formation, progression and destabilization of plaque. One of the main mediators of inflammation are white blood cells (WBC), which number increases significantly during inflammation.
Aim: The aim of this study was to determine the effect of WBC count at admission on early and long-term mortality in patients with ST segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).
Material and methods: A total of 700 consecutive STEMI patients admitted for primary PCI were included in our study. The patients included in the study were divided into two groups: group with normal and group with elevated WBC count. A leukocyte count >11000 / mm3 was considered elevated. Patinets were followed-up at 30-days and at 1-year after enrollment.
Results: Of the 700 STEMI patients treated with primary PCI, 665 had WBC count data available at admission and were included in further analysis. Of this number, elevated WBC count were registered in 380 patients (57.14%). Patients with increased WBC count were younger and smokers. Observing the characteristics of patients at admission, patients with elevated WBC count had a lower ejection fraction, higher CPK values as well as a higher incidence of heart failure. Thirty-day as well as 1-year mortality were significantly higher in patients with elevated WBC count. Patients with elevated WBC count were at three-fold higher risk for 30-day mortality and at two-fold higher risk for 1-year morality.
Conclusion: Patients with elevated WBC counts at admission had higher 30-day and 1-year mortality compared with patients with normal WBC counts. WBC count was an independent predictor of thirty-day and one-year mortality.
Keywords: white blood cell count, ST segment elevation myocardial infarction, primary percutaneous coronary intervention.
References
1. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, et al. Protective role of CXC receptor 4/ CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008;102:209–17.
2. Mozos I, Borzak G, Caraba A, Mihaescu R. Arterial stiffness in hematologic
malignancies. OncoTargets and therapy. 2017;10:1381–8.
3. Ç Yayla, Gayretli YK, Açar B, Sefe U, Goktuğ Ertem A, Kadri Akboga M, et al. White blood cell subtypes and ratios in cardiovascular disease. Angiology. 2016;68:651.
4. Gür M, Türkoğlu C, Taşkın A, Uçar H , Börekçi A, Seker T, et al. Paraoxonase-1 activity and oxidative stress in patients with anterior ST elevation myocardial
infarction undergoing primary percutaneous coronary intervention
with and without no-reflow. Atherosclerosis. 2014;234:415–20.
5. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibsonet CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion,
and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000;102:2329–34.
6. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises: laboratory reference values. N Engl J Med. 2004; 351: 1548–63.
7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39: 119-177.
8. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967; 20: 457-464.
9. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968; 405: 5-37.
10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
12. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Tei C, et al. The white blood cell count is an independent predictor of no‐reflow and mortality following acute myocardial infarction in the coronary interventional era. Annals of Medicine. 2004;36:2: 153-160.
13. Kojima S, Nonogi H, Miyao Y, Miyazaki D, Goto Y, Itoh A, et al. Is preinfarction angina related to the presence of absence of coronary plaque rupture? Heasrt. 2000; 83:64-8.
14. Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol. 1997;17:3399-405.
15. Mann DL, Young JB. Basic mechanisms in congestive heart failure: Recognizing the role of proinflammatory cytokines. Chest. 1994;105:897–904.
16. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failuailure in Framingham Heart Study subjects. Circulation. 1993;88:107–115.
17. Pellizzon GG, Dixon SR, Stone GW, Cox DA, Mattos L, Boura JA, et al. Relation of admission white blood cell count to long-term outcomes after primary coronary
angioplasty for acute myocardial infarction (the stent PAMI trial). Am
J Cardiol. 2003;91:729–31.
18. Palmerini T, Brener SJ, Genereux P, Maehara A, Della Riva D, Mariani A, et al. Relation between white blood cell count and final infarct size in patients with
ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI Trial). Am J Cardiol. 2013; 112(12): 1860–1866.